The risk of acute thromboembolic cardiovascular events in association with use of chondroitin sulphate: A comparative, propensity score-matched cohort study using Swiss healthcare claims data

Chondroitin use was associated with a slightly lower risk of cardiovascular events compared to IA steroid use. However, residual confounding by patient frailty may explain the finding to some degree, given the excess mortality in the comparison group. Further research is needed to corroborate or refute a potential cardioprotective effect of chondroitin.